{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:42:20Z","timestamp":1784288540713,"version":"3.55.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Amisulpride is a second generation atypical antipsychotic drug. The management of psychosis exacerbation in late pregnancy or during lactation is often hampered by inadequate knowledge of risk to the baby from placental transfer or breast milk transfer of drugs. There is no specific information on adverse effects from amisulpride. To gather guiding information from one mother\u2013baby pair, we conducted a drug concentration study on the fourth post-natal day and developed a novel liquid chromatography-tandem mass spectrometry method with application to the very small plasma volumes obtainable from a neonate, requiring 15 \u03bcL of plasma, and with application to human breast milk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Plasma and breast milk extracts, spiked with deuterated internal standard (amisulpride-d5) were separated isocratically with a buffered water\u2013methanol\u2013acetonitrile mobile phase. A tandem mass spectrometer in positive electrospray ionisation mode with multiple reaction monitoring was used for detection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Method linearity, sensitivity, imprecision, matrix effects, recovery, and overall process efficiency were satisfactory for milk and plasma. No interferences were found from a broad range of psychotropic and general drugs. The breast milk area under the concentration\u2013time curve for the interval 0\u201312 hours was 10,726 mcg\u00b7h\u00b7L<jats:sup>\u22121<\/jats:sup>, corresponding to a mean breast milk concentration of 894 mcg\/L. Breast milk amisulpride was 12-fold higher than the simultaneous plasma concentration. The baby's plasma amisulpride concentration was 10.5% of the maternal plasma concentration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>An assay was developed that is suitable for therapeutic drug monitoring of amisulpride. Its application to breast milk and neonate plasma showed that amisulpride partitioned strongly into breast milk and that the neonate reached plasma levels that were more than desirable for a psychotropic drug.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000300","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T17:16:50Z","timestamp":1461086210000},"page":"493-498","source":"Crossref","is-referenced-by-count":20,"title":["A Liquid Chromatography-Tandem Mass Spectrometry Method for Quantifying Amisulpride in Human Plasma and Breast Milk, Applied to Measuring Drug Transfer to a Fully Breast-Fed Neonate"],"prefix":"10.1097","volume":"38","author":[{"given":"Sean J.","family":"O'Halloran","sequence":"first","affiliation":[{"name":"PathWest Laboratory Medicine, Nedlands;"},{"name":"School of Pathology and Laboratory Medicine, University of Western Australia, Crawley;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Wong","sequence":"additional","affiliation":[{"name":"Pharmacy Department, King Edward Memorial Hospital, Subiaco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Joyce","sequence":"additional","affiliation":[{"name":"PathWest Laboratory Medicine, Nedlands;"},{"name":"School of Medicine & Pharmacology, University of Western Australia, Crawley."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FTD.0b013e3181f88f70","article-title":"Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression","volume":"32","author":"Ilett","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/bfm.2010.0016","article-title":"Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia","volume":"6","author":"Teoh","year":"2011","journal-title":"Breastfeed Med."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/0009922815594586","article-title":"A review of adverse reactions in infants from medications in breastmilk","volume":"55","author":"Anderson","year":"2016","journal-title":"Clin Pediatr (Phila)."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3797\/scipharm.1105-12","article-title":"Development and validation of amisulpride in human plasma by HPLC coupled with tandem mass spectrometry and its application to a pharmacokinetic study","volume":"79","author":"Mogili","year":"2011","journal-title":"Sci Pharm."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jchromb.2005.11.042","article-title":"Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring","volume":"831","author":"Gschwend","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jms.440","article-title":"Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography\/mass spectrometry with atmospheric pressure chemical ionization","volume":"38","author":"Kratzsch","year":"2003","journal-title":"J Mass Spectrom."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/bmc.1076","article-title":"Liquid chromatography tandem mass spectrometry method for the quantification of amisulpride with LLOQ of 100 pg\/mL using 100 microL of plasma","volume":"22","author":"Nirogi","year":"2008","journal-title":"Biomed Chromatogr."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.320","article-title":"A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers","volume":"17","author":"Rosenzweig","year":"2002","journal-title":"Hum Psychopharmacol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0447.2009.01429.x","article-title":"Amisulpride-dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring","volume":"120","author":"Sparshatt","year":"2009","journal-title":"Acta Psychiatr Scand."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2125.1992.tb04077.x","article-title":"Prospective evaluation of a model for the prediction of milk:plasma drug concentrations from physicochemical characteristics","volume":"33","author":"Begg","year":"1992","journal-title":"Br J Clin Pharmacol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds\u2013implications for pharmacokinetics of selected substrates","volume":"56","author":"El Ela","year":"2004","journal-title":"J Pharm Pharmacol."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00702-005-0367-4","article-title":"Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)","volume":"113","author":"Schmitt","year":"2006","journal-title":"J Neural Transm."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/sj.npp.1300244","article-title":"How does the benzamide antipsychotic amisulpride get into the brain?\u2013An in vitro approach comparing amisulpride with clozapine","volume":"28","author":"Hartter","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1208\/s12248-014-9649-9","article-title":"The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family","volume":"16","author":"Dos Santos Pereira","year":"2014","journal-title":"AAPS J."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.102.038315","article-title":"Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction","volume":"303","author":"Alcorn","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"key":"R20-20230814","first-page":"298","article-title":"Pharmacocin\u00e9tique et m\u00e9tabolisme de l'amisulpride","volume":"3","author":"Dufour","year":"1988","journal-title":"Ann de Psychiatrie."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201608000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:03:44Z","timestamp":1692050624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201608000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000300","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}